Q-omics provides the consensus-scored TEDDM1 profile across patient tissues and cancer cell-line models. TEDDM1 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, TEDDM1 is differentially expressed in 7, with the highest sampling consensus in THCA. Additionally, TEDDM1 RNA expression shows 15,627 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight HNSC, THCA, and THYM as cancer lineages where TEDDM1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TEDDM1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TEDDM1 survival associations across molecular data types. TEDDM1 RNA expression shows survival associations in the most cancer types (21), followed by mutation status (3). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TEDDM1 RNA expression–survival associations across cancer types. High TEDDM1 expression shows unfavorable associations in THCA and PRAD, but favorable associations in HNSC, UCS, LUSC and SCLC. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify HNSC as the clearest survival context for TEDDM1 RNA expression.
This table summarizes TEDDM1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in THCA for RNA.
This table ranks reproducible tumor–normal expression differences for TEDDM1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TEDDM1 shows lower tumor expression in THCA, KICH and UCEC and higher tumor expression in LIHC, LUSC and CHOL. The THCA box plot shows higher TEDDM1 RNA expression in normal versus tumor tissue (log2 FC = −0.235, t-test p < 0.001).
This table shows molecular features associated with TEDDM1 in patient tissues and cancer cell lines. In patient samples, TEDDM1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, TEDDM1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SKIN, while CRISPR and shRNA rows add functional-dependency signals in PANCREAS and LUNG_NSCLC_LUAD.
